BMJ Open PIM-COVID study: protocol for a multicentre, longitudinal study measuring the psychological impact of surviving an intensive care admission due to COVID-19 on patients in the UK

Alicia A C Waite 1,2, Brian W Johnston,1,2 Andrew J Boyle,3 Mary Gemma Cherry,4 Peter Fisher,4 Stephen L Brown,4,5 Christina Jones,6 Karen Williams,1 Ingeborg D Welters 1,2

ABSTRACT

Introduction Psychological distress is common in intensive care unit (ICU) survivors and is anticipated in those who were treated for severe COVID-19 infection. This trainee-led, multicentre, observational, longitudinal study aims to assess the psychological outcomes of ICU survivors treated for COVID-19 infection in the UK at 3, 6 and/or 12 months after ICU discharge and explore whether there are demographic, psychosocial and clinical risk factors for psychological distress.

Methods and analysis Questionnaires will be provided to study participants 3, 6 and/or 12 months after discharge from intensive care, assessing for anxiety, depression, post-traumatic stress symptoms, health-related quality of life and physical symptoms. Demographic, psychosocial and clinical data will also be collected to explore risk factors for psychological distress using latent growth curve modelling. Study participants will be eligible to complete questionnaires at any of the three time points online, by telephone or by post.

Ethics and dissemination The PIM-COVID study was approved by the Health Research Authority (East Midlands - Derby Research and Ethics Committee, reference: 20/EM/0247).

Trial registration number NCT05092529.

BACKGROUND

COVID-19 has led to an extraordinary demand for intensive care support for patients severely affected by SARS-CoV-2. There is an anticipated psychological impact of these intensive care admissions based on previous evidence from intensive care unit (ICU) survivors with acute respiratory distress syndrome (ARDS)1 2 and from patients treated during previous coronavirus pandemics, namely severe acute respiratory syndrome (SARS) in 2002–2003 and Middle East respiratory syndrome (MERS) in 2012–2013.3 Evidence is emerging on the impact of COVID-19 on hospitalised patients in the UK and internationally.1–7 We anticipate that the Psychological Impact of COVID-19 on Intensive Care Survivors (PIM-COVID) study will be the largest longitudinal, observational study in the UK to assess the psychological outcomes of critically ill patients who have been treated for COVID-19 infection.

Psychological symptoms after an ICU admission may form part of post-intensive care syndrome, which can also include cognitive and physical impairments that are new or have worsened following ICU admission and persist on discharge from hospital.8 In a study assessing the psychological well-being of ICU survivors up to 5 years after discharge from hospital, up to 38% of ICU patients diagnosed with non-COVID-19 ARDS were found to have prolonged symptoms of anxiety, depression and post-traumatic stress disorder (PTSD), with a median duration of symptoms...
between 33 and 39 months. Admission to critical care is itself associated with a significant burden of psychological sequelae. Symptoms of anxiety, depression and PTSD have been reported to affect up to 73% of ICU survivors. Furthermore, symptoms of anxiety, depression and PTSD can persist in up to 34% of ICU survivors after 1 year following critical care admission. At the peak of the SARS outbreak, patients reported significantly higher stress levels than healthy controls, with 64% of patients reporting symptoms suggesting psychiatric morbidity at 12 months. Recognised risk factors for emotional distress following ICU admission include previous psychiatric morbidity, receipt of benzodiazepines in ICU, physical restraint and psychiatric symptoms during their admission. Data are conflicting regarding the influence of sex on risk for experiencing psychological distress and developing long-term psychiatric morbidity after an ICU admission. Data from previous pandemics suggest that pandemic-related factors such as quarantine may also have an impact on the psychological well-being of ICU survivors.

**Study aims and objectives**

In this study, we aim to assess the short-term and long-term psychological impact on patients who have survived an admission to intensive care due to COVID-19 in the UK, and identify possible predictors of anxiety, depression and post-traumatic stress symptoms in this patient group. This is the first intensive care trainee-led multicentre study to be conducted in the UK, facilitated by the Trainee in Intensive Care (TRIC) Network and with support from the National Institute of Health Research. The TRIC Network is a UK-wide group of trainees, with an interest in intensive care medicine, who aim to facilitate audit, quality improvement and research among trainees (interns/residents) and ICU-affiliated clinicians.

Our primary objective of the study is to identify the proportion of patients surviving an admission to intensive care due to COVID-19 who experience anxiety, depression and/or post-traumatic stress symptoms at 6 months post-discharge, assessed using the Hospital Anxiety and Depression Scale (HADS) and the Impact of Event Scale-6 (IES-6), respectively. Secondary objectives are to identify demographic, clinical, physical and/or psychosocial risk factors for depression, anxiety and/or post-traumatic stress symptoms at 3, 6 and 12 months post-discharge from ICU and to assess the feasibility of using a self-reported online questionnaire to examine psychological distress in patients following ICU admission.

**METHODS AND ANALYSIS**

**Study protocol**

**Study design and setting**

PIM-COVID is a multicentre, longitudinal study involving ICUs in National Health Service hospitals in England, Northern Ireland, Scotland and Wales. Study participants have been invited to participate after discharge from intensive care, following assessment of inclusion and exclusion criteria (see Table 1). The study started in November 2020 and is due to be completed, inclusive of the substudies, in November 2023.

The study has two related components:

1. A multiple cohort design will be used for point prevalence estimates. We are seeking to obtain a large sample spanning a long time period. Thus, patients meeting the inclusion criteria will be approached up to 12 months post-ICU discharge, with some entering the study at 3, 6 and 12-month time points. Separate prevalence estimates will be made for each follow-up, with risk factor analysis from clinical data at each time point.

2. A nested single cohort design will provide longitudinal analysis. Using patients available at the 3-month and 12-month time points, we will estimate individual changes over time and conduct a longitudinal analysis of risk factors.

**Study outcomes**

The primary outcome of the study is the prevalence of anxiety, depression and post-traumatic stress symptoms in ICU survivors who have been treated for COVID-19 infection. Anxiety and depression will be assessed using the HADS. Post-traumatic stress symptoms will be assessed using the IES-6. Exploratory outcomes will use demographic, clinical and physical data (outlined in Table 2) to identify demographic, clinical, physical and/or psychosocial predictors of depression, anxiety and/or post-traumatic stress symptoms at 3, 6 and 12 months after discharge from ICU. Evaluation of psychosocial predictors will use metacognitive beliefs and processes (thoughts about beliefs and thought processes) and these will be assessed using the Cognitive Attentional Syndrome Scale-1 Revised (CAS-1R). The feasibility of using a self-reported online questionnaire to assess anxiety, depression and post-traumatic stress symptoms in patients following ICU admission will be evaluated using

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Study eligibility criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria</strong></td>
<td><strong>Exclusion criteria</strong></td>
</tr>
<tr>
<td>Adult patients aged ≥18 years</td>
<td>Unable or unwilling to consent</td>
</tr>
<tr>
<td>Diagnosed positive for COVID-19</td>
<td>Unable to complete questionnaires</td>
</tr>
<tr>
<td>Survived to intensive care unit (ICU)/high dependency unit discharge following an admission of ≥24 hours</td>
<td>Patients with diagnosed pre-existing cognitive impairment (at the time of ICU admission)</td>
</tr>
<tr>
<td>Patients with no fixed abode, at which postal questionnaires might be received, and who have no access to a personal email address.</td>
<td></td>
</tr>
</tbody>
</table>

recruitment numbers, recruitment rate (proportion of those deemed eligible recruited), retention rate (proportion of participants who provide data at subsequent data capture points) and rate of missing key data.

**Hospital and Anxiety Depression Scale**
The HADS is a 14-item self-report measure in which participants rate the presence of symptoms of anxiety (7 items) and depression (7 items) over the preceding week using a 4-point Likert scale, with options from 0 (absence) to 3 (extreme presence). Responses are summed to produce two subscale scores, ranging from 0 to 21, with higher scores indicative of higher anxiety and depression levels, respectively. The HADS is widely used to assess anxiety and depression in people with physical health difficulties and demonstrates good psychometric properties when used in an intensive care setting.\(^8\) Cut-off scores of ≥8 on anxiety and depression subscales of the HADS have been used to define caseness, with a score of 8–10 being ‘borderline abnormal’, and a score of 11–21 indicating anxiety or depression.\(^1\)\(^8\)\(^19\)

**Impact of Event Scale-6**
The IES-6 is a validated tool for survivors of ARDS to screen for PTSD. It is an abbreviated version of the Impact of Event Scale-Revised (IES-R) test and contains six questions.\(^20\) We selected the IES-6 over the IES-R because it is shorter, has been validated in a very similar patient population,\(^20\) will provide similar information to the IES-R, and is likely to have a higher completion rate by patients because of its length in the context of participants commonly experiencing a reduced concentration span following ICU admission.\(^8\) Each of the six items in IES-6 is marked on a scale of 0–4, where 0 indicates absence of distress and 4 indicates extreme distress. The mean of the six items is then calculated to give the IES-6 score. Cut-off scores of ≥1.75 indicate probable symptoms of PTSD in survivors of ARDS.\(^20\)

**EuroQol 5-dimension, 5-level questionnaire**
The EuroQol 5-dimension, 5-level questionnaire (EQ-5D-5L) is a five-domain, self-report measure assessing mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants are asked to rate each question, indicating no problems, slight problems, moderate problems, severe problems or extreme problems. In addition, participants are invited to rate their health on a Visual Analogue Scale from 0 to 100, where 0 represents the worst health imaginable and 100 represents the best health imaginable. EQ-5D-5L is the recommended questionnaire to assess the health-related quality of life of critically ill patients.\(^21\) While we will report all domains of the EQ-5D-5L, the HADS will be used to assess rates of anxiety and depression.

**Cognitive Attentional Syndrome Scale-1 Revised**
The CAS-1R is a 10-item self-report measure assessing positive and negative metacognitive beliefs, frequency of worry or rumination and the use of a range of counterproductive coping strategies used in response to negative thoughts and feelings.\(^17\) Participants are asked to rate the degree to which they have engaged in a particular coping strategy or thought process during the previous week. Responses are scaled from 0% to 100% and are summed to produce a total score. Higher scores indicate greater conviction in metacognitive beliefs and greater use of maladaptive coping strategies to manage distress. The CAS-1R has demonstrated good psychometric properties in physical health populations.\(^22\)

**Recruitment**
After discharge from ICU, patients will be screened by local study teams against inclusion and exclusion criteria prior to enrolment, with the possibility for enrolment up to 12 months after ICU discharge. Patients will be invited to participate in person while awaiting discharge from

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Data collected in the study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic data</strong></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Highest education level obtained</td>
<td></td>
</tr>
<tr>
<td>Employment status</td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status (postcode-linked deprivation index)</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical data</strong></td>
<td></td>
</tr>
<tr>
<td>Length of stay in ICU</td>
<td></td>
</tr>
<tr>
<td>Laboratory diagnosis or suspicion of COVID-19 infection</td>
<td></td>
</tr>
<tr>
<td>Mental health comorbidities pre-admission (self-reported and as documented in medical records)</td>
<td></td>
</tr>
<tr>
<td>Physical health comorbidities pre-admission</td>
<td></td>
</tr>
<tr>
<td>Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score*</td>
<td></td>
</tr>
<tr>
<td>Ventilatory support during ICU admission</td>
<td></td>
</tr>
<tr>
<td>Diagnosis of delirium during ICU admission</td>
<td></td>
</tr>
<tr>
<td>Benzodiazepine requirement during ICU admission (other than as required for intubation)</td>
<td></td>
</tr>
<tr>
<td>Date of death (if during 12-month study period)</td>
<td></td>
</tr>
<tr>
<td><strong>Functional data</strong></td>
<td></td>
</tr>
<tr>
<td>EuroQol 5-dimension, 5-level questionnaire† (EQ-5D-5L, assessing health-related quality of life. Used as a subjective assessment of the physical function of participants)</td>
<td></td>
</tr>
<tr>
<td><strong>Psychological data</strong></td>
<td></td>
</tr>
<tr>
<td>Anxiety: Hospital Anxiety and Depression Scale (HADS)† EQ-5D-5L†</td>
<td></td>
</tr>
<tr>
<td>Depression: HADS† EQ-5D-5L†</td>
<td></td>
</tr>
<tr>
<td>Psychological trauma symptoms: Impact of Event Scale-6†</td>
<td></td>
</tr>
<tr>
<td><strong>Metacognitive beliefs and processes</strong></td>
<td></td>
</tr>
<tr>
<td>Cognitive Attentional Syndrome Scale-1 Revised†</td>
<td></td>
</tr>
</tbody>
</table>

*The APACHE II score is an ICU illness severity scoring applied within the first 24 hours of admission. †Self-reported questionnaires administered at 3, 6 and/or 12 months following ICU discharge.*

hospital, while attending an ICU follow-up clinic appointment in hospital, or by postal invitation with a unique code to offer the opportunity to complete the consent form online. Questionnaires at 3, 6 and/or 12 months will be completed online, by phone or by post.

Database
Study data will be collected and managed using the online Research Electronic Data Capture (REDCap) system hosted at the University of Liverpool. Personal data will be added to the secure, web-based software platform only once patients agree to participate in the study and will be held for the study duration. Personal patient data will be pseudoanonymised for analysis and will be held in compliance with European Union General Data Protection Regulations and the UK Data Protection Act (2018).

Patient and public involvement
The peer support group charity, ICUsteps, has a group of ex-ICU patients and relatives who feed back on the importance and relevance of the research question and how they view the outcome measures being used. One of the authors, in her role as the research manager for ICUsteps, asked this group to comment on the draft research protocol using their experience of critical illness. They were also asked to comment on the possible impact for patients of taking part in the study. Patients were not involved in the recruitment to or conduct of the study.

Ancillary studies
Three substudies were designed and added to the main study, following Health Research Authority approval on 28 February 2022. Semi-structured interviews were added to the study to gain a deeper understanding of patient experience, taking into consideration feedback from patients involved in the study that the validated tools utilised in the questionnaire did not allow the nuance of their individual experiences to be conveyed. Surveying sites to understand the services available to COVID-19 survivors across the country was added to gain context to the information provided in the questionnaires in regard to whether patients engaged with follow-up services. As PIM-COVID is a trainee-led study, we added a survey of team members to understand the attitudes and opinions of collaborators and to gain their feedback on the study in a structured way.

Substudy: semistructured interviews
The aim of the semistructured interviews is to explore the experiences of critical care survivors following COVID-19 infection during their recovery phase, including perceptions about the care received and support available to them. The structure of the interview is outlined in the ‘Interview Guide’, which can be found in online supplemental material. Study participants who have indicated on a completed questionnaire that they are happy to be contacted by the study team for more information will be approached by telephone or email to discuss their potential participation in a one-on-one interview. A purposive sample of participants will be selected aiming for a sample that is diverse, representative of the cohort (in terms of ethnicity, sex, geographical location, degree of deprivation based on postcode, length of stay in ICU, etc), and inclusive of participants with and without evidence of psychological distress, based on answers to the 3 and 6 months questionnaires, where these have been answered. Participants from the last cohort of patients discharged from ICU will be invited to interview. Interviews will be conducted via Microsoft Teams or by phone and will be recorded. Audio recordings will be transcribed for analysis by a transcription service.

Substudy: survey of study team members
We aim to explore factors influencing study team member involvement, understand their attitudes and opinions, and gain feedback on the study. Team members at all study sites will be invited to complete an online survey by email, which will explore the sociodemographic characteristics of study team members, previous academic experience, feedback on involvement in the study, attitudes towards health research, barriers and motivators to contributing to health research, and future research plans.

Substudy: survey of study sites
Current national guidelines state that at-risk ICU survivors who have had an admission of more than 4 days should be invited to a follow-up clinic 2–3 months after discharge from ICU. However, hospital-based and community-based services to support ICU survivors in their recovery were limited even before COVID-19, with about 70% of hospitals not offering an ICU follow-up clinic. In this subsurvey, we aim to assess geographical differences in the availability and structure of follow-up services offered to patients with critical COVID-19 after hospital discharge. All ICUs within the UK will be approached by email and/or phone and invited to complete an online survey about follow-up services available for patients having been discharged from hospital after critical illness.

Statistical methods
We will report findings of the study using descriptive methods in the absence of a non-COVID or non-ICU comparator group. Data about ICU patients in the UK were reported by the Intensive Care National Audit and Research Centre (ICNARC) in three temporal groups related to the ‘waves’ of ICU patients admitted with COVID-19. In keeping with the date ranges used by ICNARC, we will consider study participants who were in ICU prior to 31 August 2020, between 1 September 2020 and 30 April 2021, and from 1 May 2021 onwards in addition to evaluating the overall cohort. SPSS and MPlus software will be used to conduct statistical analysis.

Multiple cohorts design
The objective is to document 3, 6 and 12 month point prevalence estimates of HADS anxiety and depression and IES-6 scores, by demographic, clinical, treatment and psychiatric history variables. Unadjusted point prevalence
rates per 100,000 individuals will be estimated with 95% CIs at 3, 6 and 12 months' observations. These separate cohorts cannot be directly compared because ICU and broader illness-related variables may change over time and thus may differ between cohorts (eg, survivor bias attributable to improved ICU care during the course of the pandemic). Demographic, clinical, treatment and psychiatric history risk factors for each cohort will be estimated using binomial logistic regression.

Single cohort design

The objective is to estimate temporal trajectories of HADS anxiety and depression, and IES-6 scores, and to prospectively predict these trajectories from demographic, clinical, treatment and psychiatric CAS-IR scores. Trajectories of HADS anxiety, depression and IES-6 scores will be described using latent growth curve modelling (LGCM). Risk factors can then be identified by fitting predictors to models, allowing for both intraparticipant and interparticipant variations to be analysed. To improve power, we will use the full range of scores for the HADS and IES-6, not categories based on putative clinical cut-off scores.

LGCM is a form of structural equation modelling that allows a temporal trajectory to be precisely estimated with regard to two parameters: a slope representing sequential changes across observations, and an intercept representing the population mean at time = 0. In this study, the intercept represents an immediate postdischarge value which will be estimated from the first (3-month) observation and slope estimates. We will adopt a conventional approach by modelling HADS anxiety and depression and IES-6 intercepts and slopes, starting from theoretical assumptions and adjusting these in relation to observed model parameters until the best compromise between initial parameters and observed data is achieved. The initial model will use known population means for HADS anxiety and depression and IES-6 as intercepts, a linear slope trajectory, with homogenous individual growth, equalities of error variance across observations and independence of slope and error estimates assumed. Linear and quadratic slope models will be specifically tested: linear models being defined as slope parameters 1, 2 and 3, representing a linear progression between 3, 6 and 12 months observations, and quadratic slopes defined as 1 + 2t + 3t^2, representing a quadratic progression between 3, 6 and 12 months observations. These separate model parameters until the best compromise between initial parameters and observed data is achieved. The initial model will use known population means for HADS anxiety and depression and IES-6 as intercepts, a linear slope trajectory, with homogenous individual growth, equalities of error variance across observations and independence of slope and error estimates assumed. Linear and quadratic slope models will be specifically tested: linear models being defined as slope parameters 1, 2 and 4, and/or psychosocial risk factors can be identified using multivariate analyses, such as regression, to predict intercept and slope. Secondary analyses will be conducted to assess temporal relationships between HADS anxiety and depression and IES-6 scores and demographic, clinical, treatment, psychiatric, CAS-IR and EQ-5D-5L variables to identify the roles of the latter as potential mediators of the scores.

Missing data

Missing variable replacement will not be used in the multiple cohorts design. Data replacement for the single cohort design will be achieved by multiple imputation for the logistic regression analysis and unbiased full information maximum likelihood estimation. Some missing variables in the single cohort will derive from the death of participants—the date of death will be provided by study teams into the online study database if the patient has died during the study period. Data will not be replaced in observations missed through death, but data obtained from these participants while alive will be used in imputation calculations.

Substudy: semistructured interviews

Analysis of the interviews will use the principles of the constant comparative method and interpretive thematic analysis. The analysis will be interpretive and consider both latent and manifest aspects of the data, thereby acknowledging both the manner that participants talk and the explicit content. Analysis will progress in parallel with recruitment and will end when theoretical saturation is reached. Systematic data coding will be performed; exceptional case analysis will be discussed within the research team; and data will be triangulated with quantitative data from the PIM-COVID study to enrich findings and interpretation.

Substudies: Survey of Study Team Members & Survey of Study Sites

The findings of both surveys will be reported using descriptive methods.

Author affiliations

1 Intensive Care Unit, Royal Liverpool University Hospital, Liverpool, UK
2 Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK
3 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
4 Department of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, UK
5 School of Psychology, University of New England, Armidale, New South Wales, Australia
6 ICUsteps, London, UK

Twitter Alicia A C Waite @aacw and Karen Williams @karen williams @kazarelli

Contributors AACW, BWJ and AJB conceived the study. The protocol was developed with the expertise of MGC, PF, SB and CJ in clinical psychological research, and CJ has advocated for patients and has represented their perspective. SB created the plan for statistical analysis. AACW, MGC and IW received funding to conduct this study. AACW, IW and KW have key roles in study implementation. AACW wrote the first draft of this protocol. All authors refined the study protocol and approved this manuscript. Honorary appointments are held by AACW and SB at the University of Liverpool and by IW at the Royal Liverpool University Hospital.

Funding Funding is provided through by the Intensive Care Society (ICS) Young Investigators Award. This covers the postage, costs of using the HADS questionnaire, statistical analysis and publication costs. Additional charitable funding was provided by the Mersey School of Anaesthesia (MSA) on application.

Disclaimer Neither the ICS as the primary funding source or the MSA had a role in the design of this study and nor will either have any role during its execution, analyses, interpretation of the data, or in the decision to submit results.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.
REFERENCES


